MGB-002

N/A

Report date: 2024/11/26 17:30:47

Base Information

Drug NameMGB-002
Drug Alias NameMGB-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsProstatic NeoplasmsLung NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMongoose Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesMongoose Bio Inc
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsLung NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A